08.02.2013 21:05 Uhr, Quelle: Wallstreet online
RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
SEOUL, South Korea, Feb. 8, 2013 /PRNewswire/ RNL BIO CO LTD (RNL) announced today the filing of an Investigational New Drug (IND) application with the Korean Food and Drug Administration (KFDA) to initiate clinical trials phase II and III …
Weiterlesen bei Wallstreet online
JustMac.info